The dyslipidemia treatment developer has filed for a $60m initial public offering that will allow Pfizer, from which it licensed its lead candidate, to exit.

US-based biopharmaceutical company Gemphire Therapeutics has filed to raise up to $60m in an initial public offering that would provide an exit to pharmaceutical firm and licensing partner Pfizer.

Gemphire is developing treatments for dyslipidemia, a condition that increases the risk of serious cardiovascular disease. Its lead candidate, Gemcabene, was licensed from Pfizer in 2011.

The IPO proceeds will support three late-stage clinical trials for Gemcabene as well as manufacturing and preclinical study-related costs for the candidate.

The Gemcabene licensing…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?